VSL#3 Treatment in Children With Crohn's Disease

NCT ID: NCT00367705

Last Updated: 2009-08-18

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE4
• Total Enrollment: 300 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2009-08-31
• Study Completion Date: 2010-12-31

Brief Summary

Crohn's disease (CD) in childhood is a chronic relapsing and remitting condition that has a significant impact on growth and development. The disease is characterized by an increased and unregulated immune response. The main therapy over the last 30 years has been corticosteroids leading to remission in 50-80% of patients within 2-4 weeks. However, the use of steroids in children is limited by side-effects including acne, moon-face, hirsutism, hypertension, metabolic disturbances and above all reduced growth. Hence, pediatricians are very interested to find alternative therapies. Therapeutic manipulation of gut flora with probiotics promises to be a useful strategy for several disorders including inflammation of the gut. The efficacy of the highly concentrated probiotic VSL#3 has been documented in maintenance and prophylaxis treatment of pouchitis in double blind, placebo controlled studies in adults. The aim of this study is to compare probiotic therapy with VSL#3 versus placebo in maintenance therapy of children with mild to moderate CD, treated with either 5-ASA, corticosteroids (local or budesonide), imuran/6 mercaptopurine (MP), as long as no change in medication dosage has been made in the previous 12 weeks (for imuran/6MP) or 4 weeks (for corticosteroids).

Detailed Description

The aim of this study is to compare probiotic therapy with VSL#3 versus placebo in maintenance therapy of children with mild to moderate CD, treated with either 5-ASA, corticosteroids (local or budesonide), imuran/6MP, as long as no change in medication dosage has been made in the previous 12 weeks (for imuran/6MP) or 4 weeks (for corticosteroids). The primary goal will be to compare their ability to maintain remission and to decrease disease activity in each of the two study groups. Data will be collected during this 16 week period regarding the safety and tolerability of VSL#3, as well as data of changes in stool composition of microflora upon treatment.

The follow up will be continued for up to 6 months with a monthly telephone questionnaire and a clinical visit at 6 months.

Study Design:

The study will be a multinational, double-blind, randomized controlled study (Munich, Paris, Rotterdam, Porto, Brussels, London, Warsaw, Chicago, Toronto, Boston, New York, Baltimore, Cleveland, Karachi and Jerusalem).

The study will include 300 children and will last for at least 16 weeks. These children will receive either 1-2 packet according to their weight; each sachet containing 900 billion bacteria/day of VSL#3 or an identical placebo, for 16 weeks.

All patients participating in this study will continue regular medications throughout the study period.

According to the Pediatric Crohn's Disease Activity Index (PCDAI) patients will be assessed clinically at regular intervals and will have stool cultured (including lactobacillus, bifidobacteria and Strep salivarius) as well as a stool calprotectin before and after treatment.

Conditions

Crohn's Disease

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

T

VSL-#3

Group Type: ACTIVE_COMPARATOR

VSL#3®

Intervention Type: DIETARY_SUPPLEMENT

1-2 sachets/day per os, 6 months

P

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DIETARY_SUPPLEMENT

1-2 sachets/day per os, 6 months

Interventions

VSL#3®

1-2 sachets/day per os, 6 months

Intervention Type: DIETARY_SUPPLEMENT

Placebo

1-2 sachets/day per os, 6 months

Intervention Type: DIETARY_SUPPLEMENT

Other Intervention Names

placebo powder

Eligibility Criteria

Inclusion Criteria

1. Children aged 6 - 18 years

2. Previous diagnosis of Crohn's disease or newly diagnosed with symptoms for at least three months before recruitment to the study.The diagnosis of CD is established by:

1. history and symptoms of the disease

2. endoscopy/histology or radiology with negative stool culture.

3. Written informed consent by parent

4. PCDAI > 12.5 and < 30

5. Treatment with 5-ASA, budesonide and imuran/6MP daily provided that the dose has remained stable for the 4 weeks (corticosteroids) or 12 weeks (for imuran/6MP) prior to inclusion. Children treated with other medications (such as anti-TNF or antibiotics including ciprofloxacilin or metronidazole) cannot enter this study.

Exclusion Criteria

1. Short bowel syndrome/ileostomy/abscess/fistula/small bowel obstruction/stenosis/stricture

2. Imminent surgery

3. Treatment with anti-TNF, systemic corticosteroids, ciprofloxacillin, metronidazole within 12 weeks of the start of the trial.

4. Participation in another clinical trial within the last 30 days.

5. Patients should not take antibiotics during the study.

6. Patients should not take opioids, cholestyramine, ursodeoxycholic acid during the study.

• Minimum Eligible Age: 6 Years
• Maximum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Hadassah Medical Organization

OTHER

Sponsor Role: lead

Responsible Party

Hadassah Medical Organization

Principal Investigators

David Branski, MD

Role: STUDY_DIRECTOR

Hadassah Medical Organization

Michael Wilschanski, MD

Role: PRINCIPAL_INVESTIGATOR

Hadassah Medical Organization

Locations

Hadassah Medical Organization,

Jerusalem, , Israel

Countries

Israel

Central Contacts

David Branski, MD

Role: CONTACT

branski@hadassah.org.il

00972-2-6777543

Facility Contacts

Arik Tzukert, DMD

Role: primary

arik@hadassah.org.il

00 972 2 6776095

Hadas Lemberg, PhD

Role: backup

lhadas@hadassah.org.il

00 972 2 6777572

References

Gionchetti P, Rizzello F, Lammers KM, Morselli C, Sollazzi L, Davies S, Tambasco R, Calabrese C, Campieri M. Antibiotics and probiotics in treatment of inflammatory bowel disease. World J Gastroenterol. 2006 Jun 7;12(21):3306-13. doi: 10.3748/wjg.v12.i21.3306.

Reference Type: BACKGROUND

PMID: 16733845 (View on PubMed)

Other Identifiers

VSL-HMO-CTIL

Identifier Type: -

Identifier Source: org_study_id